enVVeno Medical (NASDAQ:NVNO) Trading 4.2% Higher – Here’s Why

enVVeno Medical Corporation (NASDAQ:NVNOGet Free Report) traded up 4.2% during trading on Monday . The company traded as high as $3.51 and last traded at $3.46. 252,688 shares traded hands during trading, an increase of 135% from the average session volume of 107,405 shares. The stock had previously closed at $3.32.

enVVeno Medical Trading Down 4.1 %

The firm has a market cap of $44.12 million, a PE ratio of -1.99 and a beta of 1.21. The business’s 50-day simple moving average is $4.26 and its 200 day simple moving average is $4.83.

enVVeno Medical (NASDAQ:NVNOGet Free Report) last posted its earnings results on Wednesday, July 31st. The company reported ($0.31) EPS for the quarter. Analysts expect that enVVeno Medical Corporation will post -1.3 earnings per share for the current year.

Institutional Investors Weigh In On enVVeno Medical

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in enVVeno Medical by 70.6% in the first quarter. Vanguard Group Inc. now owns 573,955 shares of the company’s stock valued at $3,122,000 after acquiring an additional 237,550 shares in the last quarter. RIA Advisory Group LLC purchased a new stake in shares of enVVeno Medical during the 1st quarter valued at $238,000. Westside Investment Management Inc. boosted its position in shares of enVVeno Medical by 933.7% in the 2nd quarter. Westside Investment Management Inc. now owns 38,762 shares of the company’s stock worth $204,000 after purchasing an additional 35,012 shares in the last quarter. Kingdon Capital Management L.L.C. grew its stake in enVVeno Medical by 5.6% during the 1st quarter. Kingdon Capital Management L.L.C. now owns 653,870 shares of the company’s stock worth $3,557,000 after buying an additional 34,690 shares during the last quarter. Finally, Janney Montgomery Scott LLC acquired a new position in enVVeno Medical during the 1st quarter valued at about $186,000. Institutional investors own 34.71% of the company’s stock.

About enVVeno Medical

(Get Free Report)

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).

Read More

Receive News & Ratings for enVVeno Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enVVeno Medical and related companies with MarketBeat.com's FREE daily email newsletter.